BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig Showing Encouraging Efficacy in Advanced Triple-Negative Breast Cancer

Summary by AI BETAClose X

BioNTech and Bristol Myers Squibb announced encouraging interim Phase 2 data for their investigational bispecific antibody, pumitamig, in combination with chemotherapy for advanced triple-negative breast cancer. The treatment achieved a confirmed objective response rate of 61.5% and a disease control rate of 92.3% in first- and second-line patients, demonstrating efficacy irrespective of PD-L1 expression levels, including in PD-L1 low or negative patients. These results are consistent with prior data and support the dose selection for the pivotal Phase 3 ROSETTA BREAST-01 trial, with a manageable safety profile observed.

Disclaimer*

UK 100

Latest directors dealings